|
With the ever-expanding therapeutic market, research and development is fundamental for improving current treatments and the design of protein based drugs of the future. With the variety of protein expression systems rapidly evolving, there is more pressure to harvest larger, purer quantities of product. Furthermore, a vast number of biomarker discovery studies have recently been embarked upon, requiring new, more efficient methods to identify and analyse proteins involved in disease populations with the aim to discover novel diagnostic tools and treatments.
SMi’s 4th annual Global Protein Summit is designed to meet the needs of the industry. It is an excellent opportunity to hear about the latest developments from leaders in the field, bringing together experts in protein expression, purification, identification and functional analysis.
This event will bring together Vice Presidents, Directors, Heads and leading researchers from the pharmaceutical industry to share their knowledge and discuss the critical issues surrounding the development of innovative protein drug compounds. It’s a must attend event for all those involved in protein research and development.
Critical challenges that will be addressed: - GENE TO PROTEIN: Analyse the challenges with protein engineering and expression
- PROTEOMICS: Gain an insight into the role of biomarkers and the recent advances in this area
- PROTEIN PRODUCTION: Understand multi-parallel and high throughput systems
- EXPRESSION TECHNOLOGIES: Learn about novel technologies that are being developed for a variety of compounds
- PURIFICATION & ANALYSIS: Discuss how to effectively analyse, characterise and purify protein material
Exclusive presentations from industry experts including:
- Paul Ramage, Senior Research Investigator 1, CPC/Protease Platform, Novartis Pharma AG
- Mark McAlister, Associate Director, Protein Engineering, Global Structural Chemistry, AstraZeneca
- Florian Wurm, Professor of Biotechnology, Ecole Polytechnique Federale de Lausanne
- Joseph Siemiatkoski, Senior Scientist, Analytical Development, Biogen Idec
- Indresh Srivastava, Head of Protein Biology, Protein Biology, Novartis
- Bernardo Perez-Ramirez, Scientific Director, Bioformulations Development, Genzyme Corporation
- Mark Abbott, Principal Scientist, Respiratory and Inflammation, AstraZeneca
- Renos Savva, Senior Research Fellow, School of Crystallography, Birkbeck College, University of London
- Kent Bondensgaard, Research Scientist, Novo Nordisk
- Ingrid Marchal-Gerez, Business Development Manager, Proteus
- Ian Hunt, Group leader, Protein Structure Unit, Novartis Institute for Biomedical Research
- Linda King, Director, Oxford Expression Technologies Ltd
- Ignacio Casal, Biotechnology Programme Director and Head of the Protein Technology Unit, Centro Nacional de Investigaciones Oncológicas (CNIO)
- Balwant Patel, Director Market Development, Cloning and Protein Expression Buisness Unit, Invitrogen
- Gisela Schnapp, Principal Scientist, Lead Discovery, Strutural Research Boehringer Ingelheim Pharma
- Judit Nagy, Proteomics Facility Director, Institute of Biomedical Engineering, Imperial College London
- Laurent Fourage, Project Leader, Biotechnology, Proteus
- Nina Albrecht, Manager Scientific Sales, Geneart
- Peter Hemmerich, Research Associate, FLI Leibniz Institute for Age Research
- W. Antoni Kudlicki, Research Fellow, R&D, Invitrogen
You will benefit from attending this event if you are:
A Vice President, Director or Head of:
- Gene expression
- Biochemistry
- Proteomics
- Product Safety
| Clinical / Medical Affairs Protein expressionProtein purificationScientific Affairs | PharmacovigilanceDrug SurveillanceRegulatory AffairsPharmacokinetics |
Last years’ delegates were from:
- Pfizer
- GlaxoSmithKline
- Bayer-Schering Pharma
- Roche Products Ltd
- Merck Research Labs
| Wyeth ResearchUCB-CelltechAstraZeneca Roche Diagnostics GmbH Boehringer Ingelheim Pharma | Actelion Pharmaceuticals Ltd Labotatorios Almirall Vertex PharmaceuticalsSyngenta Evotec OAI |
|
Events Home Page
